Oppenheimer & Co. Inc. Makes New $453,000 Investment in argenx SE (NASDAQ:ARGX)

Oppenheimer & Co. Inc. acquired a new stake in shares of argenx SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 836 shares of the company’s stock, valued at approximately $453,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. O Shaughnessy Asset Management LLC boosted its position in shares of argenx by 32.8% in the first quarter. O Shaughnessy Asset Management LLC now owns 1,460 shares of the company’s stock worth $575,000 after purchasing an additional 361 shares during the period. Advisors Asset Management Inc. raised its holdings in argenx by 79.3% during the first quarter. Advisors Asset Management Inc. now owns 588 shares of the company’s stock valued at $232,000 after acquiring an additional 260 shares during the period. Toronto Dominion Bank lifted its position in shares of argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after acquiring an additional 43 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after acquiring an additional 3,900 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of ARGX opened at $600.35 on Friday. The firm has a market capitalization of $35.90 billion, a price-to-earnings ratio of -682.21 and a beta of 0.61. argenx SE has a 1-year low of $327.73 and a 1-year high of $611.22. The company has a 50-day moving average of $555.08 and a 200 day moving average of $485.94.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the previous year, the business earned ($1.25) earnings per share. On average, equities analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the subject of several recent analyst reports. Raymond James restated a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Baird R W cut shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Robert W. Baird downgraded shares of argenx from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $515.00 to $650.00 in a report on Friday, November 1st. Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Finally, Guggenheim upped their price objective on argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx presently has an average rating of “Moderate Buy” and an average target price of $630.42.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.